HALO Macrodissect Solutions

Breast Macrodissect AI accurately identifies ductal carcinoma in situ (DCIS) and excludes this non-invasive region from invasive tumor analysis. Demonstrating the algorithm’s ability to differentiate between clinically relevant tissue architecture and improving molecular testing in breast cancer.

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio

Albuquerque, NM, February 10, 2025 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio Read More »

Indica Labs Expands their Macrodissection Suite with the Launch of CRC Macrodissect AI

Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today the expansion of their macrodissection suite with the launch of CRC Macrodissect AI.

Indica Labs Expands their Macrodissection Suite with the Launch of CRC Macrodissect AI Read More »

Indica Labs Announces Launch of AI-Powered Macrodissection Suite to Advance Molecular Pathology Workflows

Albuquerque, NM – 1 August 2024 – Indica Labs, the leading provider of AI-powered digital pathology solutions, proudly announces the launch of Lung Macrodissect AI, a groundbreaking tool that revolutionizes slide macrodissection and molecular pathology workflows.

Indica Labs Announces Launch of AI-Powered Macrodissection Suite to Advance Molecular Pathology Workflows Read More »

Scroll to Top